Neogenomics Incorporated (NASDAQ:NEO) Reports Increase in Sellers; Strong Momentum for Short Players

July 18, 2017 - By Kurt Siggers

 Neogenomics Incorporated (NASDAQ:NEO) Reports Increase in Sellers; Strong Momentum for Short Players

Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.10, from 1.25 in 2016Q3. It worsened, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.
Legacy Cap reported 33,800 shares. 288,923 were reported by Bard Associate Inc. Eam Investors Ltd Liability Co has invested 0.24% in NeoGenomics, Inc. (NASDAQ:NEO). Principal Fincl Grp owns 21,619 shares or 0% of their US portfolio. Arrowstreet Capital Ltd Partnership accumulated 216,826 shares or 0.01% of the stock. Vanguard Incorporated stated it has 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). 47 are held by Qs Invsts Limited Liability. Teton Advisors accumulated 181,407 shares. Panagora Asset Mgmt has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Moreover, Legal & General Group Public Limited Co has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 13,516 shares. Intll Gp reported 0% in NeoGenomics, Inc. (NASDAQ:NEO). Falcon Point Capital Ltd Liability reported 0.29% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Barclays Plc stated it has 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Citigroup invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Illinois-based Castleark Limited Liability has invested 0.27% in NeoGenomics, Inc. (NASDAQ:NEO).

Since March 13, 2017, it had 0 insider purchases, and 4 selling transactions for $1.10 million activity. Shares for $132,400 were sold by BRODIE STEVEN G. on Monday, March 13. BALLIET JENNIFER sold 3,334 shares worth $25,005. ROSS STEVEN A also sold $549,389 worth of NeoGenomics, Inc. (NASDAQ:NEO) on Friday, June 2.

The stock of Neogenomics Incorporated (NASDAQ:NEO) registered an increase of 1.18% in short interest. NEO’s total short interest was 6.88M shares in July as published by FINRA. Its up 1.18% from 6.80M shares, reported previously. With 379,200 shares average volume, it will take short sellers 18 days to cover their NEO’s short positions. The short interest to Neogenomics Incorporated’s float is 12.81%.

The stock increased 0.33% or $0.03 during the last trading session, reaching $9.24. About shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since July 18, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The company has market cap of $736.95 million. The Firm operates in Laboratory Testing Segment. It currently has negative earnings. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 9 analysts covering NeoGenomics (NASDAQ:NEO), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. NeoGenomics has $11 highest and $8 lowest target. $10.07’s average target is 8.98% above currents $9.24 stock price. NeoGenomics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. As per Sunday, September 6, the company rating was maintained by William Blair. The rating was maintained by Roth Capital with “Buy” on Thursday, September 3. Cantor Fitzgerald initiated NeoGenomics, Inc. (NASDAQ:NEO) rating on Thursday, December 15. Cantor Fitzgerald has “Overweight” rating and $11 target. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Sell” rating by Axiom Capital on Wednesday, November 16. The company was initiated on Friday, March 11 by Benchmark. On Friday, May 26 the stock rating was maintained by Roth Capital with “Buy”. TH Capital reinitiated NeoGenomics, Inc. (NASDAQ:NEO) on Monday, October 26 with “Buy” rating. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, May 26 by Cantor Fitzgerald. As per Tuesday, October 4, the company rating was initiated by First Analysis. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Wednesday, May 11 by Roth Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.